How much does the targeted drug Ceritinib cost?

Ceritinib/Ceritinib (Ceritinib) is an oral anti-cancer drug that belongs to the tyrosine kinase inhibitor category. As a targeted therapy drug, it is mainly used to treat patients with a specific type of non-small cell lung cancer (NSCLC), that is, patients who are ALK (tyrosine kinase) fusion positive.

Ceritinib/Ceritinib has been launched in China and has been included in medical insurance. Patients can purchase it domestically, but the price is high. Please consult your local pharmacy for details. Foreign original drugs are divided into original drugs and generic drugs. Foreign original drugs are mainly Swiss Novartis original drugs. Specification150mg*150The price is about13,500 yuan. Generic drugs mainly include Bangladeshi version, with specifications of 150mg*30 and the price is around 1,300 yuan. The ingredients of original drugs and generic drugs are basically the same.

ALK fusion-positive non-small cell lung cancer is a specific subtype of lung cancer. The ALK gene and other gene fusions exist in its cancer cells, resulting in abnormal activity of ALK kinase, promoting the growth and spread of cancer cells. Ceritinib/Ceritinib works against this abnormal ALK fusion protein. By inhibiting its activity, it blocks the proliferation and spread of cancer cells, thereby inhibiting the development of tumors.

Ceritinib/Ceritinib was developed in clinical trials and ultimately approved by the U.S. Food and Drug Administration (FDA) and recognized by drug regulatory agencies in other countries. In the United States, it is sold under the brand name Zykadia.

Usingceritinib/ceritinibTreatmentALKFusion-positive non-small cell lung cancer patients can bring significant therapeutic effects, especially those who are ineffective or resistant to traditional chemotherapy. However, like any drug, Ceritinib/Ceritinib may also cause some adverse reactions, including nausea, vomiting, diarrhea, fatigue and other common minor reactions, as well as rare but serious lung problems, arrhythmia, etc.